148 related articles for article (PubMed ID: 29934842)
1. Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival.
Ito K; Saito S; Yorozu A; Kojima S; Kikuchi T; Higashide S; Aoki M; Koga H; Satoh T; Ohashi T; Nakamura K; Katayama N; Tanaka N; Nakano M; Shigematsu N; Dokiya T; Fukushima M;
Int J Clin Oncol; 2018 Dec; 23(6):1148-1159. PubMed ID: 29934842
[TBL] [Abstract][Full Text] [Related]
2. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
[TBL] [Abstract][Full Text] [Related]
3. Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS).
Saito S; Ito K; Yorozu A; Aoki M; Koga H; Satoh T; Ohashi T; Shigematsu N; Maruo S; Kikuchi T; Kojima S; Dokiya T; Fukushima M; Yamanaka H
Int J Clin Oncol; 2015 Apr; 20(2):375-85. PubMed ID: 24840041
[TBL] [Abstract][Full Text] [Related]
4. Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience.
Sylvester JE; Grimm PD; Wong J; Galbreath RW; Merrick G; Blasko JC
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):376-81. PubMed ID: 20864269
[TBL] [Abstract][Full Text] [Related]
5. Five-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the UK.
Dickinson PD; Malik J; Mandall P; Swindell R; Bottomley D; Hoskin P; Logue JP; Wylie JP
BJU Int; 2014 May; 113(5):748-53. PubMed ID: 24053230
[TBL] [Abstract][Full Text] [Related]
6. Permanent interstitial low-dose-rate brachytherapy for patients with low risk prostate cancer: An interim analysis of 312 cases.
Badakhshi H; Graf R; Budach V; Wust P
Strahlenther Onkol; 2015 Apr; 191(4):303-9. PubMed ID: 25339309
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen 'bounce' after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis.
Satoh T; Ishiyama H; Matsumoto K; Tsumura H; Kitano M; Hayakawa K; Ebara S; Nasu Y; Kumon H; Kanazawa S; Miki K; Egawa S; Aoki M; Toya K; Yorozu A; Nagata H; Saito S; Baba S
BJU Int; 2009 Apr; 103(8):1064-8. PubMed ID: 19040526
[TBL] [Abstract][Full Text] [Related]
8. Direct Comparison of Two Different Definitions with Biochemical Recurrence after Low-Dose-Rate Brachytherapy for Prostate Cancer.
Takeuchi S; Iinuma K; Nakane K; Nakano M; Kawase M; Kawase K; Takai M; Kato D; Mori T; Takano H; Kumano T; Matsuo M; Koie T
Curr Oncol; 2023 Feb; 30(3):2792-2800. PubMed ID: 36975425
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications.
Stock RG; Stone NN; Cesaretti JA
Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):448-53. PubMed ID: 12738319
[TBL] [Abstract][Full Text] [Related]
10. Outcomes following iodine-125 prostate brachytherapy with or without neoadjuvant androgen deprivation.
Ohashi T; Yorozu A; Saito S; Momma T; Toya K; Nishiyama T; Yamashita S; Shiraishi Y; Shigematsu N
Radiother Oncol; 2013 Nov; 109(2):241-5. PubMed ID: 24183866
[TBL] [Abstract][Full Text] [Related]
11. Biochemical relapse-free survival in 400 patients treated with I-125 prostate brachytherapy: the Guildford experience.
Nobes JP; Wells IG; Khaksar SJ; Money-Kyrle JF; Laing RW; Langley SE
Prostate Cancer Prostatic Dis; 2009; 12(1):61-6. PubMed ID: 18427571
[TBL] [Abstract][Full Text] [Related]
12. Seed migration after transperineal interstitial prostate brachytherapy by using loose seeds: Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS) multi-institutional cohort study.
Nakano M; Yorozu A; Saito S; Sugawara A; Maruo S; Kojima S; Kikuchi T; Fukushima M; Dokiya T; Yamanaka H
Radiat Oncol; 2015 Nov; 10():228. PubMed ID: 26577301
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent iodine implants.
Prada PJ; Juan G; González-Suárez H; Fernández J; Jimenez I; Amón J; Cepeda M
BJU Int; 2010 Jul; 106(1):32-6. PubMed ID: 20067460
[TBL] [Abstract][Full Text] [Related]
14. Biochemical outcomes and predictive factors by risk group after permanent iodine-125 seed implantation: Prospective cohort study in 2,316 patients.
Katayama N; Nakamura K; Yorozu A; Kikuchi T; Fukushima M; Saito S; Dokiya T
Brachytherapy; 2019; 18(5):574-582. PubMed ID: 31153759
[TBL] [Abstract][Full Text] [Related]
15. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S
Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671
[TBL] [Abstract][Full Text] [Related]
16. Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer.
Miles EF; Nelson JW; Alkaissi AK; Das S; Clough RW; Broadwater G; Anscher MS; Chino JP; Oleson JR
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):139-46. PubMed ID: 19836161
[TBL] [Abstract][Full Text] [Related]
17. Dosimetry and cancer control after low-dose-rate prostate brachytherapy.
Robert Lee W; Deguzman AF; McMullen KP; McCullough DL
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):52-9. PubMed ID: 15629593
[TBL] [Abstract][Full Text] [Related]
18. Genitourinary toxicity after permanent iodine-125 seed implantation: The nationwide Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS).
Tanaka N; Yorozu A; Kikuchi T; Higashide S; Kojima S; Ohashi T; Katayama N; Nakamura K; Saito S; Dokiya T; Fukushima M;
Brachytherapy; 2019; 18(4):484-492. PubMed ID: 31072729
[TBL] [Abstract][Full Text] [Related]
19. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time.
Ciezki JP; Reddy CA; Garcia J; Angermeier K; Ulchaker J; Mahadevan A; Chehade N; Altman A; Klein EA
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):512-7. PubMed ID: 16213667
[TBL] [Abstract][Full Text] [Related]
20. Prostate specific antigen bounce is related to overall survival in prostate brachytherapy.
Hinnen KA; Monninkhof EM; Battermann JJ; van Roermund JG; Frank SJ; van Vulpen M
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):883-8. PubMed ID: 21300477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
